BTIG assumed coverage of Alpha Teknova with a Buy rating and $6.00 price target. The company is a leading provider of customized reagents which are sold to over 3,000 customers across the life sciences industry, including in molecular diagnostics, therapeutics, and vaccines, having recently undergone a strategic pivot from offering off-the-shelf products to driving greater focus on producing higher-value, made-to-order, customized reagents, the analyst tells investors in a research note. Alpha Teknova has only recently made investments in commercial teams and next-generation lab automation and should now be able to reap the fruit of its investments, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TKNO:
- Teknova to Participate in Upcoming Investor Conference
- Teknova Reports First Quarter 2023 Financial Results
- Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting
- Alpha Teknova launches proprietary AAV-Tek solutions gene therapy product line